## 2017. OCTAVE 1&2

## Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

Randomized double-blind, placebo-controlled trial. Patients with moderate-to-severe UC randomised to: OCTAVE Induction 1 and 2: TOFA 10 mg/BD vs placebo for 8w.

<u>Primary endpoint:</u> remission w8. <u>OCTAVE sustain</u>: those on remission randomized to 5mg BD or

10mg BD or placebo Primary endpoint: remission w52

## Results:

-Induction 1: remission w8, 18.5% Tofa vs 8.2% pbo; p=0.007

- -Induction 2: remission w8, 16.6% Tofa vs 3,6% pbo; p<0.001
- Sustain: 34.3% (5mg) vs 40.6% (10mg) vs 11.1% pbo; p<0.001 for both comparisons.

- Increased risk of infection and higher cholesterol levels in Tofacitinib than placebo.

Conclusions:

In moderate-severe UC tofacitinib is more effective as induction and maintenance than placebo.




Figure 1. Primary and Key Secondary End Points.

H